GlobeNewswire by notified

Harbert European Growth Capital Announces Final Close

Share

LONDON, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Harbert European Growth Capital (“HEGCF”), is pleased to announce the final close of its second fund (“Fund II”) at €215 million, a substantial increase over Harbert European Growth Capital Fund I (“Fund I”).  HEGCF, which provides debt capital to fund growth opportunities across technology, life science and other innovative sectors attracted significant institutional capital, as well as numerous family office investors.  “We are grateful for the support and trust that our existing and new investors have placed in us,” said David Bateman, Senior Managing Director and co-head of HEGCF.

“The market opportunity remains strong with many companies across Europe seeking expansion funding of various forms,” notes Johan Kampe, Senior Managing Director and co-head of HEGCF. It has been a busy start with Fund II already having closed investments in 21 new companies since the first close in summer 2017.

HECGF also continues to have follow on investing activity into the Fund I portfolio and has made four follow on investments.  HEGCF would like to welcome the following Fund II companies:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/23c227c0-85bc-46d3-971e-469d65b25ceb

About Harbert European Growth Capital Fund II, SCSp

HEGCF provides expansion capital, typically in the form of debt, to European growth businesses, predominantly in the technology, life sciences and environmental sectors. Typical loan sizes range from €1-30+ million with the flexibility to do larger transactions opportunistically. We look for investment opportunities in high growth businesses with proven management teams in need of capital to fuel organic growth, acquisitions, equipment purchases, bridge loans and various forms of recapitalization.

About Harbert Management Corporation

Harbert European Growth Capital Fund II, SCSp is sponsored by Harbert Management Corporation (“HMC”) and closed to new investors on August 31, 2018.  HMC, an alternative asset management firm with approximately $5.9 billion in Regulatory Assets Under Management as of August 31, 2018 is a privately owned firm formed in 1993 to sponsor alternative asset investment funds.  HMC serves foundations and endowments, fund of funds, pension funds, financial institutions, insurance companies, family offices, and high net worth individuals across multiple asset classes.  Investment strategies include European and U.S. real estate, seniors housing, U.S. growth capital, credit solutions, independent power, European growth equity, and hedge funds.  Additional information about HMC can be found at www.harbert.net.

Contact: Harbert Investor Relations
Telephone: 205.987.5500
E-mail: irelations@harbert.net

 

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

SPEVIGO® approved for expanded indications in China and the US19.3.2024 12:00:00 CET | Press release

Generalized pustular psoriasis (GPP) is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin and systemic symptoms, such as fever, pain, and fatigue1,2,3,4In China, SPEVIGO®’s expanded approval adds the reduction of occurrences of GPP in pediatric patients aged 12 and above weighing ≥40 kg, and adults5The US FDA’s approval expands the use of SPEVIGO® to include the treatment of GPP in adults and pediatric patients aged 12 and above weighing ≥40 kg, making it the first targeted therapy that addresses the need for acute and chronic treatment for GPP patients6SPEVIGO® is currently approved in 48 countries7 Boehringer Ingelheim today announced that the US Food and Drug Administration (FDA) has approved SPEVIGO® (spesolimab-sbzo) injection for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and above weighing ≥40 kg.5 This approval follows the Chinese National Medical Products Administration’s (NMPA) recent appro

Equinor ASA: Kjøp av aksjer til aksjeprogram for ansatte19.3.2024 11:57:54 CET | Pressemelding

Nedenfor følger informasjon om transaksjoner knyttet til tilbakekjøpsprogrammet for Equinor ASA (OSE:EQNR, NYSE:EQNR) til bruk i aksjebaserte insentivprogrammer for ansatte og ledelse. Dato for annonsering av tilbakekjøpsprogrammet: 7. februar 2024. Varighet av tilbakekjøpsprogrammet: 15. februar 2024 til 15. januar 2025. Størrelse av tilbakekjøpsprogrammet: Samlet kjøpesum i tilbakekjøpsprogrammet er inntil NOK 1.156.000.000 og det maksimale antall aksjer som kan erverves er 16.800.000, hvorav opp til 7.400.000 aksjer kan erverves i perioden fra 15. februar 2024 til 15. mai 2024, og opptil 9.400.000 aksjer kan erverves i perioden fra 16. juni 2024 til 15. januar 2025. Den 15. mars 2024 kjøpte Equinor ASA totalt 482.159 egne aksjer ved Oslo Børs til en gjennomsnittspris på NOK 279,9906 pr. aksje. Oversikt over transaksjoner: DateAggregert volum (antall aksjer)Vektet gjennomsnittspris pr. aksje (NOK) Total transaksjonsverdi (NOK) 15 mars 2024482.159279,9906134.999.988Totalt tidligere of

Equinor ASA: Buy-back of shares to share programmes for employees19.3.2024 11:57:54 CET | Press release

Please see below information about transactions made under the buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR) for shares to be used in the share-based incentive programmes for employees and management. Date on which the buy-back programme was announced: 7 February 2024. The duration of the buy-back programme: 15 February 2024 to 15 January 2025. Size of the buy-back programme: The total purchase amount under the programme is NOK 1,156,000,000 and the maximum shares to be acquired is 16,800,000 shares, of which up to 7,400,000 shares can be acquired in the period from 15 February 2024 to 15 May 2024, and up to 9,400,000 shares can be acquired in the period from 16 May 2024 to 15 January 2025. On 15 March 2024, Equinor ASA has purchased a total of 482,159 own shares at the Oslo Stock Exchange at an average price of NOK 279.9906 per share. Aggregated overview of transactions per day: DateAggregated volume (number of shares)Weighted average share price (NOK) Total transaction val

Annual General Meeting 202419.3.2024 11:54:34 CET | Press release

To Nasdaq OMX Copenhagen A/S Public announcement no. 554 March 19th, 2024 NOTICE OF ANNUAL GENERAL MEETING IN GLUNZ & JENSEN HOLDING A/S Glunz & Jensen Holding A/S announces that the annual general meeting for the company will be held on April 10th, 2024, at 13.00 at: Glunz & Jensen Holding A/S Selandia Park 2 4100 Ringsted The notice is in accordance with the company's financial calendar. The notice has been submitted in accordance with the company's Articles of Association § 3. Glunz & Jensen will update its website just prior to the annual general meeting and the upload will contain the presentation intended for the annual general meeting. The documents are attached to this notice and further information can be obtained on the company's website (www.glunz-jensen.com). For further information please contact: CEO Henrik Blegvad Funk: phone +45 21 39 05 32 Chairman of the board Flemming Nyenstad Enevoldsen: phone +45 40 43 13 03 Attachments Indkaldelse til generalforsamling - notice to

Wren Kitchens Completes 56% More Customer Appointments and Saves £2 million Annually with Descartes Routing Solution19.3.2024 11:45:00 CET | Press release

LONDON and ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that the U.K.’s leading kitchen retailer, Wren Kitchens, is using Descartes’ dynamic appointment scheduling, route planning and optimisation solution to improve surveyor productivity allowing them to complete 56% more customer appointments and significantly reduce its overall ‘cost per appointment’, which has saved the company £2million annually. The solution has dramatically improved the productivity of Wren’s surveyors, who typically visit a customer’s home to provide estimates for kitchen or bedroom renovation projects. “As the business expanded, we outgrew our legacy in-house system. We wanted a more robust tool with the ability to book appointments with 2-hour time slots and optimize who, where and when a surveyor visits to carry out customer estimates,” said Lee Holmes, Transport and Logistics Di

HiddenA line styled icon from Orion Icon Library.Eye